Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab
David O. Bates(Brigham and Women's Hospital), Steven J. Harper(Northwestern University), Al B. Benson(Northwestern University), Alexander H. R. Varey(Melanoma Institute Australia), Neal J. Meropol(Flatiron Health (United States)), Paul J. Catalano(Computational Physics (United States)), Kirsty E. Symonds(Northwestern University), Bruce J. Giantonio(Northwestern University), Pramila Ramani(Northwestern University), Peter J. O’Dwyer(University of Pennsylvania)
Cited by 79
Related Papers
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|1.4k